Evidence strength for the context described on this page.
PEPTIDE ATLAS / COGNITION & SLEEP / SELANK
Not FDA-approvedInsufficient
Selank
ALSO KNOWN ASTP-7
An anxiolytic peptide analog with limited human evidence and no approved U.S. product.
01CATEGORYCognition & sleep
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEIntranasal in international product use; injectable forms are unapproved and less studied
04DOSE BASISInternational label + reported clinic use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Selank is.
A synthetic analog related to the immunomodulatory peptide tuftsin, marketed for anxiety, focus and emotional regulation.
HOW IT IS THOUGHT TO WORK
Proposed to affect GABAergic signaling, neurotrophic factors and immune-neural communication.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established treatment effect for anxiety or cognition under U.S. evidence standards
- Replacement for psychotherapy or approved medication
- Cognitive enhancement
- Long-term safety
- A standardized nasal dose
Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
International label + reported clinic useRegistered Russian-product range: 300 mcg intranasally three times daily—900 mcg/day—for 10–14 days. Current clinic sources often publish 300–600 mcg/day in divided intranasal doses. These are international-label or market-use numbers, not an FDA-approved U.S. anxiety regimen.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Intranasal doses divided 2–3 times daily for 10–14 days; some clinics extend to 2–4 weeks without strong long-term evidence.
- How to interpret it
- Concentration per drop or spray varies. This is not an FDA-approved substitute for psychotherapy or established anxiety treatment, and injectable Selank has far less human context than the intranasal product.
- Route
- Intranasal in international product use; injectable forms are unapproved and less studied
- Duration
- Registered/reported courses: 10–14 days; longer clinic cycles are not validated
- Men & women
- No validated male/female protocol; reported ranges do not differ routinely by sex.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- Use validated mental-health screening and clinical follow-up rather than subjective stack tracking alone
SAFETY
Risks, red flags and reasons to avoid it.
- Insufficient human safety information
- Immunogenicity and peptide-related impurities
- Nasal irritation
- Interaction uncertainty with psychiatric medicines
- Stopping psychiatric medication
- Pregnancy
- Self-treatment of severe anxiety
- Unverified products
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Gray-market and some compounded availability; not FDA-approved.
Calmness claims are difficult to separate from expectation effects without rigorous blinded trials.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP